Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News
Financial Results · Q1 2026

Neuphoria Therapeutics Q1 2026 Results: Net Loss of $1.43M, Loss Narrows

Neuphoria Therapeutics Inc., formerly Bionomics Limited, completed its re-domiciliation from Australia to Delaware in December 2024. As of November 13, 2026, the company reported 5,411,334 shares of common stock outstanding and is currently pursuing a proposed merger with Scancell Holdings plc.

Q1 2026 at a glance · $ million
MetricQ1 2026Q1 2025
Profit before tax-1.5-9.9
Net income-1.4-9.9
EPS (diluted, $ a share)$-0.26$-4.41

A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.

Source

10-Q filed with the SEC, NASDAQ: NEUP. Figures from the filing's XBRL data; summary written with AI assistance from the filing.

Read the filing ↗

Neuphoria Therapeutics Inc.: key numbers

Share price
$2.27Close, Nov 17
Market cap
$12.3M
Shares outstanding
5.41MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834

Today's reference numbers, updated daily. Not a valuation or a recommendation.

More from Neuphoria Therapeutics Inc.

All →
8:00 AM ET 8-K
Other 8-K Filing

Neuphoria Therapeutics Other 8-K Filing

Neuphoria Therapeutics Inc. has extended its existing shareholder rights agreement (poison pill) for an additional year. The amendment extends the final expiration date of the rights from October 27, 2026, to October 27, 2027. This corporate governance measure is typically used to deter unsolicited takeover attempts by making a hostile acquisition significantly more expensive.

Counterparty
Computershare Trust Company, N.A.
Term
1 year

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.